In a report released today, Jeffrey Hung from Morgan Stanley maintained a Sell rating on Evofem Biosciences (EVFM – Research Report), with a price target of $0.75. The company’s shares closed last Friday at $0.89, close to its 52-week low of $0.28.
According to TipRanks.com, Hung is a 5-star analyst with an average return of 23.5% and a 56.7% success rate. Hung covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Ultragenyx Pharmaceutical, and ACADIA Pharmaceuticals.
Evofem Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $2.31.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $14.93 and a one-year low of $0.28. Currently, Evofem Biosciences has an average volume of 29.14M.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EVFM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Evofem Biosciences, Inc. develops therapeutic solutions to meet sexual and reproductive health needs of women. Its product include Amphora Contraceptive for the prevention of pregnancy, antimicrobial drug product for the prevention of sexually transmitted infections and Antimicrobial Drug product to prevent the reoccurrence of bacterial vaginosis. The company was founded in 2007 and is headquartered in San Diego, CA.
Read More on EVFM:
